Future development of drug candidates inhibiting TOX–DNA interactions could follow previous studies where SMIs have been successfully developed via CADD to target the DNA-binding domains of other cancer drug targets, such as AR [12], ERG [14], and MYC [15]. This evidence concerns the gene ERG and cancer.